共 310 条
[61]
Fleischmann R(2009)Assessing the impact of efalizumab on nail, scalp and palmoplantar psoriasis and on quality of life: results from a multicentre, open-label, phase IIIb/IV trial Arch Drug Inf. 3 1568-2564
[62]
Deodhar AA(2010)Efalizumab in the treatment of scalp, palmoplantar and nail psoriasis: results of a 24-week Latin American study Arch Drug Inf. 168 2560-559
[63]
Umezawa Y(2013)A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis Br J Dermatol 23 552-456
[64]
Asahina A(2009)Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis J Eur Acad Dermatol Venereol 36 453-553
[65]
Imafuku S(2022)Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab J Eur Acad Dermatol Venereol 33 549-623
[66]
Mease P(2022)Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study J Dermatolog Treat 44 619-916
[67]
Elaine Husni M(2017)Efficacy and safety of dose escalation of infliximab therapy in Japanese patients with psoriasis: results of the SPREAD study J Dermatol 159 2631-100
[68]
Chakravarty SD(2008)Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study Br J Dermatol 25 914-329
[69]
Kavanaugh A(2011)Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients J Eur Acad Dermatol Venereol 314 96-128
[70]
McInnes I(2022)Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period Arch Dermatol Res 35 325-942